Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-Year median follow-up

British Journal of Cancer

Volumn 80, Issue 3-4, 1999, Pages 419-426

  Harbeck, N ^a   Dettmar, P ^b   Thomssen, C ^c   Berger, U ^b   Ulm, K ^b   Kates, R ^b   Hofler H ^b   Janicke F ^c   Graeff, H ^a   Schmitt, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Breast cancer; Plasminogen activator inhibitor type 1 (PAI 1); Prognosis; S phase fraction; Tumour biology; Urokinase type plasminogen activator (uPA)

Indexed keywords

CATHEPSIN D; KI 67 ANTIGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P53; STEROID RECEPTOR; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; COMPARATIVE STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE NEU; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TUMOR VOLUME;

EID: 0032944657     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690373     Document Type: Article

References (45)

1. Bagwell CB, Mayo SW, Whetstone SD, Hitchcox SA, Baker DR, Herbert DJ, Weaver DL, Jones MA and Lovett EJ (1991) DNA histogram debris theory and compensation. Cytometry 12: 107-118
2. Benraad TJ, Geurts-Moespot J, Grøndahl-Hansen J, Schmitt M, Heuvel JJTM, deWitte JH, Foekens JA, Leake RE, Brünner N and Sweep CGJ (1996) Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 workshop. Eur J Cancer 32A: 1371-1381
3. Blankenstein MA (1997) Biochemical assessment of tissue prognostic factors in breast cancer. Breast 6: 31-37
4. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A and Oglobine J (1994) Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405
5. Breiman I, Friedman J, Olshen R and Stone C (1984) Classification and Regression Trees. Chapman and Hall: New York
6. Brown RW, Allred CD, Clark GM, Osborne C and Hilsenbeck S (1996) Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 2: 585-592
7. Clark GM (1996) Prognostic and predictive factors. In: Diseases of the Breast. Harris JR, Lippmann ME, Morrow M and Hellmann S (eds), pp. 461-485. Lippincott-Raven: Philadelphia
8. Clark GM and McGuire W (1988) Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15: 20-25
9. Cox DR (1972) Regression models and life-tables. J R Stat Soc (B) 34: 187-200
10. Danø K, Andreasen PA, Grøhndahl-Hansen J, Kristensen P, Nielsen L and Skriver L (1985) Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266
11. Dettmar P, Harbeck N, Thomssen C, Pache L, Ziffer P, Fizi K, Jänicke F, Nathrath W, Schmitt M, Graeff H and Höfler H (1997) Prognostic impact of the proliferation associated factors Ki-67 and S-phase in node-negative breast cancer using MIB1 immunostaining and flowcytofluorometric S-phase determination. Br J Cancer 75: 1525-1533
12. D'hautcourt JL, Spyratos F and Chassevent A, on behalf of the Association Francaise de Cytometric (1996) Quality control study by the French cytometry association on flow cytometric DNA content and S-phase fraction (S%). Cytometry (Comm Clin Cytometry) 26: 32-39
13. Duffy MJ, Reilley D, O'Sullivan C, O'Higgins N, Fennelly JN and Andreasen P (1990) Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829
14. Elston CW and Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-410
15. Fernö M, Bendahl PO, Borg A, Brundell J, Hirschberg L, Olsson H and Killander D (1996) Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 32A: 793-801
16. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MD, Jänicke F and Klijn JGM (1994) Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncology 12: 1648-1658
17. Gasparini G, Boracchi P, Verderio P and Bevilacqua P (1994) Cell kinetics in human breast cancer: Comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 57: 822-829
18. Graeff H, Wilmanns W, Jänicke F, Sauer H and Classen S (1997) Prognostische und therapierelevante Faktoren beim Mammakarzinom. Ergebnisse einer Konsensuskonferenz. Onkologe 3: 409-412
19. Grøhndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K and Blichert-Toft M (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
20. Grøhndahl-Hansen J, Christensen IJ, Briand P, Pappot H, Mouridsen HT, Blichert-Toft M, Danø K and Brünner N (1997a) Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients. Clin Cancer Res 3: 233-239
21. Grøhndahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK and Brünner N (1997b) Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat 43: 153-163
22. Harbeck N, Yamamoto N, Moniwa N, Schüren E, Ziffer P, Dettmar P, Höfler H, Schmitt M and Graeff H (1994) Flow cytometric DNA analysis in primary breast cancer: technical pitfalls and clinical applications. In: Prospects in Diagnosis and Treatment of Cancer, Schmitt M, Graeff H and Jänicke F (eds), pp. 63-74. Elsevier Science: Amsterdam
23. Harbeck N, Dettmar P, Thomssen C, Hensetmann B, Kuhn W, Ulm K, Jänicke F, Höfler H, Graeff H and Schmitt M (1998) Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res 18: 2187-2198
24. Harris JR, Lippman ME, Veronesi U and Willett W (1992) Medical progress: breast cancer (third of three parts). N Engl J Med 327: 473-490
25. Hiddemann W, Schumann J, Andreeff M, Barlogie B, Herman CJ, Leif RC, Mayall BH, Murphy RF and Sandberg AA (1984) Convention on nomenclature for DNA cytometry. Cytometry 5: 445-446
26. Hilsenbeck SG and Clark GM (1996) Practical p-value adjustment for optimally selected cutpoints. Stat Med 15: 103-112
27. Kaplan EL and Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
28. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W and Graeff H (1990) Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
29. Jänicke F, Schmitt M and Graeff H (1991) Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer, Semin Thromb Hemostasis 17: 303-312
30. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H and Graeff H (1993) Urokinase (uPA) and its inhibitor PAI-1 are strong, independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208
31. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A and Graeff H (1994a) Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54: 2527-2530
32. Jänicke F, Thomssen C, Pache L, Schmitt M and Graeff H (1994b) Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In Prospects in Diagnosis and Treatment of Cancer. Schmitt M, Graeff H and Jänicke F (eds), pp. 207-218. Elsevier Science: Amsterdam
33. Lauffenburger D (1996) Making connections count. Nature 383: 390-391
34. McGuire W and Clark GM (1992) Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 326: 1756-1761
35. Osborne CK (1989) DNA flow cytometry in early breast cancer: a step in the right direction. J Natl Cancer Inst 81: 1344-1345
36. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR and Flom KJ (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904
37. Ravdin PM (1993) Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat 24: 219-226
38. Rochefort H (1992) Cathepsin D in breast cancer: a tissue marker associated with metastasis. Eur J Cancer 28A: 1780-1783
39. Schmitt M, Jänicke F and Graeff H (1992) Tumor-associated proteases. Fibrinolysis 6: 3-26
40. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning C, Ulm K, Höfler H, Jänicke F and Graeff H (1997a) Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thrombosis Haemostasis 78: 285-296
41. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F and Graeff H (1997b) Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer. Br J Cancer Inst 76: 306-311
42. Spyratos F, Martin PM, Hacène K, Romain S, Andrieu C, Ferrero-Poüs M, Deytieux S, LeDoussal V, Tubiana-Hulin M and Brunet M (1992) Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266-1272
43. Stefansson S and Lawrence DA (1996) The serpin PAI-1 inhibits cell migration by blocking integrin α,β, binding to vitronectin. Nature 383: 441-443
44. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV and Chapman HA (1996) Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555
45. Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM and McGuire W (1993) DNA ploidy, S-phase, and storoid receptors in more than 127 000 breast cancer patients. Breast Cancer Res Treat 28: 9-20